Pharmacoeconomics of liposomal anthracycline therapy

Seminars in Oncology

Volumn 31, Issue SUPPL. 13, 2004, Pages 191-195

  Bennett, Charles L ^a,b   Calhoun, Elizabeth A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG FEVER; DRUG TOLERABILITY; ECONOMIC ASPECT; HAND FOOT SYNDROME; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KAPOSI SARCOMA; LEUKOPENIA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; PHARYNGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMATITIS; THROMBOCYTOPENIA;

EID: 11144265306     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.08.008     Document Type: Article

References (25)

1. D.A. Freund, R.S. Dittus Principles of pharmacoeconomic analysis of drug therapy Pharmacoeconomics 1 1992 20 31
2. J.D. Rizzo, N.R. Powe Methodological hurdles in conducting pharmacoeconomic analyses Pharmacoeconomics 15 1999 339 355
3. P.E. Greenberg, A. Arcelus, H.G. Birnbaum Pharmacoeconomics and health policy. Current applications and prospects for the future Pharmacoeconomics 16 1999 425 432
4. E.A. Calhoun, C.L. Bennett Pharmacoeconomics of amifostine in ovarian cancer Semin Oncol 26 1999 102 107
5. A.S. Detsky, I.G. Naglie A clinician's guide to cost-effectiveness analysis Ann Intern Med 113 1990 147 154
6. C.E. Reeder Overview of pharmacoeconomics and pharmaceutical outcomes evaluations Am J Health Syst Pharm 52 1995 S5 S8
7. L.M. Jolicoeur, A.J. Jones-Grizzle, J.G. Boyer Guidelines for performing a pharmacoeconomic analysis Am J Hosp Pharm 49 1992 1741 1747
8. J.F. Bishop, K. Macarounas-Kirchman The pharmacoeconomics of cancer therapies Semin Oncol 24 1997 S19-106 S19-111
9. Doxil (doxorubicin HCl liposome injection) prescribing information 2001 Ortho Biotech Products, LP Bridgewater, NJ
10. DaunoXome (daunorubicin citrate liposome injection) prescribing information 2002 Gilead Sciences, Inc San Dimas, CA
11. C.L. Bennett, R.M. Golub, T.J. Stinson Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma J Acquir Immune Defic Syndr Hum Retrovirol 18 1998 460 465
12. S. Stewart, H. Jablonowski, F.D. Goebel International Pegylated Liposomal Doxorubicin Study Group Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma J Clin Oncol 16 1998 683 691
13. P.S. Gill, J. Wernz, D.T. Scadden Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J Clin Oncol 14 1996 2353 2364
14. C. Hjortsberg, U. Persson, E. Lidbrink Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma Acta Oncol 38 1999 1063 1067
15. A.N. Gordon, J.T. Fleagle, D. Guthrie Recurrent epithelial ovarian carcinoma A randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
16. K.J. O'Byrne, P. Bliss, J.D. Graham A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer Proc Am Soc Clin Oncol 21 2002 203A (abstr 808)
17. M.L. Hensley, B. Hoppe, L. Leon The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients Gynecol Oncol 82 2001 464 469
18. D.H. Smith, J.R. Adams, S.R. Johnston A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK Ann Oncol 13 2002 1590 1597
19. S. Capri, G. Cattaneo Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy Clin Ther 25 2003 1826 1845
20. B. Ojeda, L.M. De Sande, A. Casado Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain Br J Cancer 89 2003 1002 1007
21. C. Forbes, J. Wilby, G. Richardson A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer Health Technol Assess 6 2002 1 119
22. M.A. Hussein, M. Wildgust, J. Fastenau Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma Proc Am Soc Clin Oncol 23 2004 567 (abstr 6548)
23. M.S. Ewer, F.J. Martin, I.C. Henderson Cardiac safety of liposomal anthracyclines Semin Oncol 31 suppl 13 2004 161 181
24. M. Bates, D. Lieu, M. Zagari A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer Clin Ther 19 1997 167 184
25. M.R. Bristow, M.B. Lopez, J.W. Mason Efficacy and cost of cardiac monitoring in patients receiving doxorubicin Cancer 50 1982 32 41